Developing a Nature Inspired Nanoparticle Drug Delivery System


DLVR Therapeutics Inc. is a privately held biotechnology company based in Toronto, Ontario, Canada.  Founded in 2011, the company is focused on developing a novel, HDL-mimicking nanoparticle delivery system for nucleotides, such as small interfering RNA (siRNA). The ultra-small DLVR technology – which is nontoxic, biocompatible, and biodegradable – exploits a critical property of HDL biology to create a hydrophobic channel in the cell membrane, thus enabling the delivery of an siRNA payload directly into the cytosol of a target cell. In doing so, the DLVR technology overcomes a major challenge with current delivery approaches that typically target the endosome, thereby exposing the nucleotide payload to enzymatic degradation.